{"id":"NCT01606228","sponsor":"Janssen Pharmaceutica","briefTitle":"A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia","officialTitle":"An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER Among Treatment-Na√Øve and Newly Diagnosed Patients With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2012-05-25","resultsPosted":"2012-10-22","lastUpdate":"2012-10-22"},"enrollment":188,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Paliperidone ER","otherNames":[]}],"arms":[{"label":"Paliperidone ER","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.","primaryOutcome":{"measure":"The Proportion of Patients Improving 20% in Total Positive and Negative Syndrome Scale (PANSS) at Endpoint (Day 90)","timeFrame":"Baseline, Day 90","effectByArm":[{"arm":"Paliperidone Extended-release (ER)","deltaMin":97.73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":188},"commonTop":["Insomnia","Anemia","Hypertension","Pyrexia","Extra-Pyramidal Symptoms"]}}